Test Price
3,500 AED✅ Home Collection Available
PD‑L1 (Dako 22C3) Immunohistochemistry Test in UAE – 3500 AED – DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited, CAP‑aligned immunohistochemistry processing with automated digital scoring.
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – temperature‑controlled chain for archival FFPE blocks or slides.
- Clinical Guidance: Complimentary telephonic post‑test interpretation support by our oncology‑trained advisors.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731 – instant reply within 60 seconds.
Test Overview & Methodology
The PD‑L1 (Dako 22C3) IHC assay quantifies programmed death‑ligand 1 expression on formalin‑fixed paraffin‑embedded (FFPE) tissue, serving as a pivotal companion diagnostic for immune checkpoint inhibitor therapy in non‑small cell lung cancer and other solid tumours. The test is performed on the Dako Autostainer Link 48 platform using the validated 22C3 antibody clone, with digital scoring for Tumour Proportion Score (TPS) determination. Reporting follows CAP and UAE regulatory standards.
| Feature | DNA Labs UAE – Dako 22C3 pharmDx | Conventional IHC Alternative |
|---|---|---|
| Precision | Automated, validated clone (22C3) with digital scoring | Variable clones, manual scoring, lower reproducibility |
| Methodology | IHC on Autostainer Link 48 platform | Manual IHC with subjective interpretation |
| Turnaround Time | 7–8 working days | Often 10–14 days |
| UAE Regulatory Compliance | Fully compliant with UAE PDPL & health data protection laws | May lack local data privacy guarantees |
Physician Insight & Safety Protocols
A positive PD‑L1 result indicates potential eligibility for immune checkpoint inhibitor therapy, but it must be interpreted alongside tumour histology, disease stage, and your overall clinical status. Always discuss the full report with your treating oncologist before initiating or modifying any treatment regimen. Our CAP‑aligned laboratory combines rigorous quality assurance with patient‑centred support throughout the diagnostic journey.
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
⚠️ Medication Advisory
Never discontinue or alter prescribed immunotherapy or other medications without explicit direction from your treating physician. Treatment decisions must be made by your oncologist based on the complete clinical picture.
Exclusion Criteria & Emergency Red Flags
- Inadequate FFPE tissue block with insufficient tumour content or degraded sample.
- Active bleeding disorder or anticoagulation that cannot be safely interrupted for biopsy.
- Pregnancy without explicit oncologist approval – test limited to maternal benefit assessment.
- Minors (<18 years) requiring mandatory parental consent under UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Seek emergency care if you experience: severe pain, uncontrolled bleeding, or signs of infection at the biopsy site.
Patient FAQ & Clinical Guidance
1. What is the PD‑L1 (Dako 22C3) test and why is it ordered?
Answer: This assay measures PD‑L1 protein expression on tumour cells from a preserved tissue sample. It helps oncologists determine whether a patient is likely to benefit from pembrolizumab or other immune checkpoint inhibitor therapies, particularly in non‑small cell lung cancer and selected solid tumours.
2. How is the test performed and what do I need to provide?
Answer: A formalin‑fixed paraffin‑embedded (FFPE) tumour tissue block from a prior biopsy or surgery is required. The block is sectioned, stained with the Dako 22C3 antibody on an automated platform, and digitally scored by a CAP‑accredited pathologist. Slides may be accepted after preliminary pathologist review.
3. What do the results mean and how are they interpreted?
Answer: The report provides a Tumour Proportion Score (TPS) expressed as a percentage. A TPS of 50% or higher generally indicates greater potential benefit from anti‑PD‑1 therapy. Results must be correlated with tumour type, stage, and clinical history by your oncologist.
UAE Regulatory & Data Privacy Adherence
🔒 Your Data, Your Rights – Fully Compliant with UAE Law
All patient data and clinical records are processed and stored exclusively within UAE‑based secure servers, encrypted end‑to‑end. Our practices adhere to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and safety protocols follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
✅ ISO 9001:2015 Certified (Certificate No. INT/EGQ/2509DA/3139)
📞 Support: WhatsApp +971 54 548 8731 (8 AM–11 PM daily) for booking, insurance verification, or clinical guidance.
Clinical & Logistical Metadata
| Test Name | PD‑L1 (Dako 22C3) Immunohistochemistry |
| Price (AED) | 3,500 AED |
| Turnaround Time | 7–8 working days |
| Sample Type / Matrix | Formalin‑Fixed Paraffin‑Embedded (FFPE) Tissue Block – Archival Tissue Specimen |
| Methodology Used | Immunohistochemistry (IHC) – Automated staining on Dako Autostainer Link 48 platform with digital TPS scoring |
| ICD‑10‑CM Code | C80.1, Z51.12, Z85.3 |
| LOINC Code | 88210‑9 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians